Hjem › Crohns sykdom › Kentucky
Kliniske studier for Crohns sykdom i Kentucky
12 studier for Crohns sykdom søker deltakere på steder i Kentucky.
Byer i Kentucky
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Louisville Hospital ( Site 5120), Louisville
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284144, Louisville
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Tri-State Gastroenterology Associates, Crestview Hills
RekruttererFase 4
Alder 18 til 80 · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Kentucky Chandler Medical Center /ID# 265564, Lexington
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Tri-State Gastroenterology Assoc, Crestview Hills
- University of Louisville - MedCenter One, Louisville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University Of Louisville, Louisville
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Health Partners, Louisville
RekruttererFase 3
Alder 18 til 70 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of Kentucky/Markey Cancer Center, Lexington
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University of Kentucky Hospital/UK Albert B. Chandler Hospital-Site Number: 8400058, Lexington
RekruttererFase 3
Alder 16 til 80 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07184931A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Louisville, Louisville
RekruttererFase 4
Alder 18 til 70 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Tri-State Gastroenterology Assoc, Crestview Hills
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT07577843Treatment of Moderate to Severe Refractory Crohn's Disease
- University of Louisville, Louisville
RekruttererFase 1/2
Alder 18 til 65 · Alle kjønn · Oppdatert 10. des. 2025 · NCT06721962Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.